XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis

Yan, Ye; Liang, Hongjie; Light, Morning; Li, Taijie; Deng, Yan; Li, Meng; Li, Shan; Qin, Xue

doi:10.1007/s13277-013-1256-3

Cited by 22 publications

(19 citation statements)

References 48 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have demonstrated that a defect of the DNA repair function is a risk factor for several kinds of cancer, including bladder cancer, acute leukemia, and breast cancer (Yan et al, 2014;Liu et al, 2014). reported a meta-analysis with 11 studies, including 3797 cases and 5094 controls, and showed that polymorphism in ERCC2 rs13181 contributes to bladder cancer susceptibility.…”

Section: Discussionmentioning

confidence: 99%

“…reported a meta-analysis with 11 studies, including 3797 cases and 5094 controls, and showed that polymorphism in ERCC2 rs13181 contributes to bladder cancer susceptibility. Yan et al (2014) conducted a meta-analysis with 22 studies, and reported that polymorphism in ERCC2 rs13181 significantly increased breast cancer risk. Liu et al (2014) performed a meta-analysis with ten published case-control studies including 1494 cases and 2259 controls, and reported that the ERCC2 rs13181 variant genotype might be a risk factor for acute leukemia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Several studies have focused on the association between the ERCC2 rs13181 polymorphism and glioma risk, but the results were inconclusive. We aimed to conduct a meta-analysis to investigate the role of ERCC2 rs13181 on the risk of glioma. We searched and collated the relevant studies in both Chinese and English through the PubMed, Web of Science, Cochrane Library, and EMBASE databases published through June 1, 2014. A total of 11 studies for ERCC2 rs13181 were selected; these included 3456 glioma cases and 4957 controls. Using fixed-effects model analysis, we found that no significant difference could be identified between the ERCC2 rs13181 polymorphism and the risk of glioma. Subgroup analysis showed that the ERCC2 rs13181 GT and TT genotypes were significantly associated with an increased risk of glioma in the Chinese population [odds ratio (OR) = 1.47, 95% confidence interval (CI) = 1.17-1.85; and OR = 1.50, 95%CI = 1.02-2.22, respectively], but no significant increased risk of glioma was detected with these genotypes in the Caucasian populations. No T.L. Jia et al. 12578©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 12577-12584 (2015) publication bias was identified in this meta-analysis. Our meta-analysis strongly suggested that ERCC2 rs13181 was associated with a higher susceptibility to glioma in the Chinese population.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…On the whole, three newly updated meta-analyses revealed that there were no evidence supporting that XPD Lys751Gln polymorphism contributed to prostate cancer (Ma et al, 2013) , colorectal cancer (Zhang et al, 2011) , or gastric cancer (Yin et al, 2013). On the contrary, other large sample meta-analyses proposed a greater risk in hepatocellular carcinoma (Guo et al, 2012), breast cancer (Yan et al, 2014), lung cancer , glioma (Chen et al, 2012), and acute myeloid leukemia (AML) (Liu et al, 2014). For XPD Asp312Asn polymorphism, three meta-analyses proposed a greater risk in prostate cancer (Ma et al, 2013), gastric cancer (Yin et al, 2013), and esophageal cancer (Duan et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

“…For XPD Asp312Asn polymorphism, three meta-analyses proposed a greater risk in prostate cancer (Ma et al, 2013), gastric cancer (Yin et al, 2013), and esophageal cancer (Duan et al, 2012). However, other large sample meta-analyses showed that it did not contribute to breast cancer (Yan et al, 2014), lung cancer , colorectal cancer (Zhang et al, 2011) or head and neck cancer (Hu et al, 2012) risk.…”

Section: Discussionmentioning

confidence: 99%

XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies

Zhu¹,

Bao²,

Lin³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Numerous studies have explored the influence of XPD Lys751Gln and/or Asp312Asn polymorphisms on skin cancer susceptibility. However, the results remain inconclusive. To derive a more precise estimation, we conducted a comprehensive search to identify all available published studies and performed a meta-analysis. Materials and Methods: Electronic literature searches of the PubMed, CBM and CNKI databases were performed up to March 2014. Odds ratios (ORs) with 95% confidence intervals (CIs) were applied to assess the strength of associations. Results: Seventeen case-control studies were included with a total sample size of 6, 113 cases and 11, 074 controls for the XPD Lys751Gln polymorphism, and 10 studies (3, 840cases and 7, 637 controls) for the XPD Asp312Asn polymorphism were pooled for analysis. Overall, no significant associations were found between the XPD Lys751Gln polymorphism and skin cancer risk in any genetic model. On stratified analysis by tumor type, XPD Lys751Gln polymorphism was not associated with increased risk of non-melanoma skin cancer, but was significantly related with increased risk of cutaneous melanoma (Gln/Gln vs Lys/Lys: OR=1.15, 95%CI=1.02-1.29, p=0.023; dominant model: OR=1.09, 95%CI=1.01-1.18, p=0.036). For the XPD Asp312Asn polymorphism, no significant association with skin cancer risk was observed in overall or subgroup analyses. Conclusions: The present meta-analysis suggests that the XPD Lys751Gln polymorphism may contribute to the risk of cutaneous melanoma from currently available evidence. Further investigations are needed to obtain more insight into possible roles of these two polymorphisms in skin carcinogenesis.

show abstract

“…Asp312Asn and Lys751Gln polymorphisms are the two most widely investigated ERCC2 polymorphisms associated with increased DNA adduct levels and with low DNA repair capacity (Lunn et al, 2000), which suggests that these two SNPs may contribute to carcinogenesis and can be regarded as risk factors for cancer development. Recently, many systematic reviews and meta-analyses have been performed to examine the association of ERCC2 polymorphisms with various cancers (Duan et al, 2012;Yin et al, 2013;Huang et al, 2014;Liu et al, 2014;Xin et al, 2014;Yan et al, 2014;Zhu et al, 2014) except for NHL. What's more, epidemiological studies investigating the association of ERCC2 polymorphisms with NHL risk in populations of different ethnic origin have been published, but the results remain inconclusive (Shen et al, 2006;Smedby et al, 2006;Shen et al, 2007;Song et al, 2008;Baris et al, 2009;Worrillow et al, 2009;Yang et al, 2009;El-Din et al, 2013;Fabisiewicz et al, 2013;Kim et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Assessment of Associations between ERCC2 Lys751Gln/Asp312Asn Polymorphisms and Risk of Non-Hodgkin Lymphoma

Zhou

He²,

Liu³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Excision repair crossing-complementing group 2 (ERCC2), also called xeroderma pigmentosum complementary group D (XPD), plays a crucial role in the nucleotide excision repair (NER) pathway. Previous epidemiological studies have reported associations between ERCC2 polymorphisms and non-Hodgkin lymphoma (NHL) risk, but the results have remained controversial. Materials and Methods: We conducted this metaanalysis based on eligible case-control studies to investigate the role of two ERCC2 polymorphisms (Lys751Gln and Asp312Asn) in determining susceptibility to NHL. Ten case-control studies from several electronic databases were included in our study up to August 14, 2014. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed-or random-effects models to estimate the association strength. Results: The combined results based on all studies did not show any association between Lys751Gln/Asp312Asn polymorphisms and NHL risk for all genetic models. Stratified analyses by histological subtype and ethnicity did not indicate any significant association between Lys751Gln polymorphism and NHL risk. However, a significant reduced risk of NHL was found among population-based studies (Lys/Gln versus Lys/Lys: OR=0.87, 95% CI=0.77-0.99, P=0.037) but not hospital-based studies. As for Asp312Asn polymorphism, there was no evidence for the association between this polymorphism and the risk of NHL in all subgroup analyses. Conclusions: This meta-analysis suggests that there may be no association between Lys751Gln/Asp312Asn polymorphism and the risk of NHL and its two subtypes, whereas ERCC2 Lys751Gln heterozygote genotype may provide protective effects against the risk of NHL in population-based studies. Therefore, large-scale and well-designed studies are needed to clarify the effects of haplotypes, gene-gene, and gene-environment interactions on these polymorphisms and the risk of NHL and its different histological subtypes in an ethnicity specific population.

show abstract

XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis

Cited by 22 publications

References 48 publications

Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis

Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis

XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies

Comprehensive Assessment of Associations between ERCC2 Lys751Gln/Asp312Asn Polymorphisms and Risk of Non-Hodgkin Lymphoma

Contact Info

Product

Resources

About